SPONSOR
FBD Biologics Limited
Total Trials
2
Recruiting
2
Phases
Phase 1
FBD Biologics Limited is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma.
The trial portfolio spans Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — FBD Biologics Limited
How many clinical trials has FBD Biologics Limited sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by FBD Biologics Limited, of which 2 are actively recruiting participants. These trials cover conditions including Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does FBD Biologics Limited research focus on?
FBD Biologics Limited clinical trials span Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma. The research pipeline includes Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a FBD Biologics Limited clinical trial?
To participate in a FBD Biologics Limited trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all FBD Biologics Limited trials with current recruitment status updated daily.
Clinical Trials by FBD Biologics Limited
NCT05892718 Phase 1
Recruiting
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Advanced Solid Tumor
NCT06487624 Phase 1
Recruiting
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
Advanced Solid Tumor
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology